Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Randomised Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
2018-000137-13Phase 3Completed
- Sponsor
- Orphazyme A/S
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Arimoclomol 1200 mg/day with Placebo (2 arms). Primary endpoint: Combined Assessment of Function and Survival (CAFS). Started Sep 2018; status: completed.
02
Drugs
arimoclomol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2018-000137-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000137-13.